BARD1 and breast carcinoma: Neoadjuvant chemotherapy offers opportunity to assess the molecular changes of heterogenic breast cancer tissue before and after chemotherapy, especially in the case of TNBC, in which BARD1 gene deleterious alterations are the most prevalent and NACT seem to have the greatest value.